ClinicalTrials.gg
RecruitingNCT07031687Updated Aug 21, 2026

Effects and Mechanisms of Temporal Interference Brain Stimulation on Memory Function in Preclinical Alzheimer's Disease

An interventional study of Active TIBS and Sham TIBS in Alzheimer Disease, sponsored by Xuanwu Hospital, Beijing. Recruiting at 2 sites in China. Open to participants aged 60 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-08-21.

Sponsored by Xuanwu Hospital, Beijing · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,200
Allocation
Randomized
Ages
60 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 26 studies in Alzheimer Disease by Xuanwu Hospital, Beijing — 19 open to participants now, 20 under way, 1 of them phase 3. Alzheimer Disease · Xuanwu Hospital, Beijing.

Planned enrollment
Largest of 19
1,200 · median 40
Started
2025
with 7 others
No phase
13 of 26
8 open now
Primary completion
2028-12
later than 12 of 19 live
Registered
18th of 26
by date

Among the 26 studies in Alzheimer Disease by Xuanwu Hospital, Beijing, this one has the largest planned enrollment of the 19 interventional ones that give a count, is one of 8 that started in 2025, is one of 13 with no phase, reaches primary completion later than 12 of the 19 other live ones, and was the 18th registered.

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

19 of the 26 studies in Alzheimer Disease by Xuanwu Hospital, Beijing are open now, in 1 country. Recruiting first, the newest first:

13 more — sign in →

By country, each count listing its studies:

All 19 open studies →

Where they have run

Who these studies take

Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.

This study: 60 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Alzheimer Disease by Xuanwu Hospital, Beijing, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if personalized, multimodal imaging-guided, EEG-based closed-loop Temporal Interference Brain Stimulation (TIBS) can improve memory function in individuals with preclinical Alzheimer's Disease (AD).

The main questions it aims to answer are:

  1. Does personalized TIBS lead to significant changes in functional connectivity strength of hippocampal-cortical networks at the end of the 2-week intervention compared to baseline?
  2. What are the short-term (end of 2-week intervention) and medium-to-long-term (4 weeks and 12 weeks post-intervention) effects of personalized TIBS on episodic and working memory, as well as other cognitive domains in preclinical AD?
  3. How does personalized TIBS modulate brain activity and connectivity, as measured by EEG power spectra and functional MRI (fMRI) functional connectivity, in preclinical AD?
  4. What is the safety profile of personalized TIBS in this population?

Researchers will compare participants receiving active personalized TIBS to participants receiving sham (inactive) stimulation to see if TIBS effectively improves memory function and induces neural plasticity.

Participants will:

  1. Undergo initial screening including neuropsychological assessments and blood p-tau217 testing to identify preclinical AD.
  2. Receive either active personalized TIBS or sham stimulation daily for 40 minutes, 6 days a week, for 2 weeks.
  3. Have individualized TIBS parameters (e.g., target localization, intensity) determined using baseline structural MRI and DTI.
  4. Undergo real-time high-density EEG monitoring during daily stimulation sessions to enable closed-loop adjustment of stimulation parameters.
  5. Participate in follow-up assessments at the end of the 2-week intervention, and at 4 weeks and 12 weeks post-intervention.
  6. Receive multimodal imaging (sMRI, rs-fMRI, task-fMRI, DTI) and blood biomarker assessments at various time points.
  7. Receive Aβ-PET and tau-PET scans, along with comprehensive neuropsychological assessments, at the 12-week follow-up.
  8. Have their safety continuously monitored throughout the study.
03

Conditions studied

  • Alzheimer Disease

Browse trials for

04

Who can participate

Ages eligible
60 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Individuals recruited from neurology memory clinics or communities.
  • Age between 60 and 80 years old, inclusive; no gender limitation.
  • Right-handed.
  • Cognitive function test results within normal range after age, gender, and education-level adjustment, OR mild cognitive impairment not yet meeting diagnostic criteria for Mild Cognitive Impairment (MCI), OR only subjective cognitive decline.
  • Individuals classified as preclinical AD based on the revised 2024 AD diagnostic and staging criteria (i.e., cognitively normal with positive plasma p-tau217 or positive Aβ PET).
  • Full understanding of the study, voluntary participation, and provision of written approved by the Ethics Committee.

Exclusion criteria

Exclusion Criteria:

  • Past or present neurological diseases (e.g., stroke, epilepsy, Parkinson's disease, multiple sclerosis).
  • Psychiatric disorders such as severe depression or severe anxiety.
  • Systemic diseases causing cognitive decline (e.g., severe thyroid dysfunction, severe liver or kidney disease, severe nutritional deficiencies).
  • Currently taking medications that may affect cognitive function (e.g., anticholinergics, benzodiazepines, antipsychotics) that cannot be discontinued or adjusted.
  • Other factors leading to cognitive decline that are not AD-related.
  • for MRI scans, such as claustrophobia, implanted metallic devices (e.g., pacemakers, cochlear implants, aneurysm clips), or history of head injury with retained metal fragments.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
1,200 participants (estimated)

Study arms

  • Experimental
    Personalized Closed-Loop Temporal Interference Brain Stimulation

    Participants in this arm will receive active TIBS targeted at the bilateral hippocampus. Stimulation parameters include a 5 Hz (Theta band) low-frequency modulation envelope, generated by two high-frequency current pairs (e.g., f1=2000 Hz, f2=2005 Hz). Peak-to-peak current intensity for each pair will be 2 mA (or 1 mA per electrode). Stimulation will be delivered daily for 40 minutes, 6 days/week, for a total of 2 weeks. Individualized targeting and initial intensity optimization will be guided by baseline sMRI and DTI. Real-time high-density EEG monitoring during each daily session (D2-D11) will provide feedback on brain activity (e.g., EEG power spectra, functional connectivity features) to enable closed-loop optimization of transcranial stimulation intensity and phase parameters.

    Device: Active TIBS

  • Sham comparator
    Sham Temporal Interference Brain Stimulation

    Participants in this arm will receive sham stimulation designed to mimic the sensation of active TIBS without therapeutic output. This will involve using a sham coil or a device mode with extremely low current intensity (e.g., 0.1-0.2 mA) or brief ramp-up/ramp-down sensations at the beginning and end of sessions, with no effective current delivery during the main stimulation period. The stimulation position and apparent parameters will be identical to the active TIBS group to maintain blinding.

    Device: Sham TIBS

Interventions

  • DeviceActive TIBS

    Participants receive active TIBS targeted at the bilateral hippocampus. Stimulation parameters include a 5 Hz (Theta band) low-frequency modulation envelope, generated by two high-frequency current pairs (e.g., f1=2000 Hz, f2=2005 Hz). Peak-to-peak current intensity for each pair will be 2 mA (or 1 mA per electrode). Stimulation is delivered daily for 40 minutes, 6 days/week, for a total of 2 weeks. Individualized targeting and initial intensity optimization are guided by baseline sMRI and DTI. Real-time high-density EEG monitoring during each daily session (D2-D11) provides feedback on brain activity

  • DeviceSham TIBS

    Participants receive sham stimulation designed to mimic the sensation of active TIBS without therapeutic output. This involves using a sham coil or a device mode with extremely low current intensity (e.g., 0.1-0.2 mA) or brief ramp-up/ramp-down sensations at the beginning and end of sessions, with no effective current delivery during the main stimulation period. The stimulation position and apparent parameters are identical to the active TIBS group to maintain blinding.

06

What researchers measure

Primary outcomes

  1. Change from Baseline in Functional Connectivity Strength of Hippocampal-Cortical Networks

    Quantified by resting-state fMRI (rs-fMRI) functional connectivity strength within and between key memory-related networks (e.g., default mode network, hippocampal-cortical network) at the end of the 2-week intervention. Specific metrics will include ALFF, ReHo, FCS, and ACF.

    Time frame: Baseline, End of 2-week intervention.

Secondary outcomes

  1. Changes from Baseline in Hippocampal Gray Matter Density (sMRI)

    Evaluation of changes in hippocampal gray matter density or volume, quantified using structural Magnetic Resonance Imaging (sMRI). This measure assesses the structural integrity and potential atrophy or increase in gray matter in a key brain region associated with memory.

    Time frame: Baseline, End of 2-week intervention, 4 weeks post-intervention, 12 weeks post-intervention

  2. Changes from Baseline in Cortical Thickness (sMRI)

    Evaluation of changes in cortical thickness across various brain regions, quantified using structural Magnetic Resonance Imaging (sMRI). This measure assesses the integrity and potential thinning or thickening of the cerebral cortex.

    Time frame: Baseline, End of 2-week intervention, 4 weeks post-intervention, 12 weeks post-intervention

  3. Changes from Baseline in Resting-State Functional Connectivity (fMRI)

    Evaluation of changes in resting-state functional connectivity using functional Magnetic Resonance Imaging (fMRI). This assesses the temporal correlations between spontaneous fluctuations in BOLD signals across different brain regions, reflecting synchronized neural activity. Specific brain networks (e.g., Default Mode Network, Salience Network) or seed-based connectivity will be analyzed.

    Time frame: Baseline, 4 weeks post-intervention, 12 weeks post-intervention

  4. Changes from Baseline in White Matter Integrity (DTI)

    Evaluation of changes in white matter integrity, assessed using Diffusion Tensor Imaging (DTI). Key metrics to be analyzed include Fractional Anisotropy (FA), Mean Diffusivity (MD), Axial Diffusivity (AD), and Radial Diffusivity (RD), reflecting the directionality and magnitude of water diffusion in white matter tracts.

    Time frame: Baseline, End of 2-week intervention, 4 weeks post-intervention, 12 weeks post-intervention

  5. Changes from Baseline in AD Molecular Pathologies and Blood Biomarkers

    Evaluation of brain amyloid-beta (Aβ) deposition via Aβ-PET imaging, brain tau pathology via tau-PET imaging, and dynamic changes in plasma biomarkers (e.g., p-tau217, Aβ42/40 ratio, NfL, GFAP, α-synuclein, BDNF).

    Time frame: Baseline, 12 weeks post-intervention

  6. Changes from Baseline in Auditory Verbal Learning Test-H (AVLT-H) Score

    Measures episodic memory. The Auditory Verbal Learning Test - Delayed Recall (AVLT-H) score typically represents the number of words recalled after a delay. Full Scale Name: Auditory Verbal Learning Test-H Minimum Value: 0 Maximum Value: Delayed Recall--12; Recognition--24 Higher Scores Mean: Better memory.

    Time frame: Baseline, End of 2-week intervention, 4 weeks post-intervention, 12 weeks post-intervention

  7. Changes from Baseline in n-back Task Performance Score

    Measures working memory. Performance on the n-back task is typically measured by accuracy (percentage of correct responses) or the highest 'n' level achieved. Full Scale Name: n-back Task Performance Minimum Value: 0% accuracy or lowest 'n' level Maximum Value: 100% accuracy or highest 'n' level tested Higher Scores Mean: Better working memory.

    Time frame: Baseline, End of 2-week intervention, 4 weeks post-intervention, 12 weeks post-intervention

  8. Changes from Baseline in Mini-Mental State Examination (MMSE) Score

    Measures global cognitive function. Full Scale Name: Mini-Mental State Examination (MMSE) Minimum Value: 0 Maximum Value: 30 Higher Scores Mean: A better global cognitive function.

    Time frame: Baseline, End of 2-week intervention, 4 weeks post-intervention, 12 weeks post-intervention

  9. Changes from Baseline in Montreal Cognitive Assessment - Basic (MoCA-B) Score

    Measures global cognitive function. Full Scale Name: Montreal Cognitive Assessment - Basic (MoCA-B) Minimum Value: 0 Maximum Value: 30 Higher Scores Mean: A better global cognitive function.

    Time frame: Baseline, End of 2-week intervention, 4 weeks post-intervention, 12 weeks post-intervention

  10. Changes from Baseline in Verbal Fluency Test Score

    Measures language function. The score represents the number of words generated. Full Scale Name: Verbal Fluency Test Minimum Value: 0 Maximum Value: None Higher Scores Mean: A better verbal fluency.

    Time frame: Baseline, End of 2-week intervention, 4 weeks post-intervention, 12 weeks post-intervention

  11. Changes from Baseline in Boston Naming Test (BNT) Score

    Measures language function. The score represents the number of words generated. Full Scale Name: Boston Naming Test Minimum Value: 0 Maximum Value: 30 Higher Scores Mean: A better naming ability.

    Time frame: Baseline, End of 2-week intervention, 4 weeks post-intervention, 12 weeks post-intervention

  12. Changes from Baseline in Shape trails test A&B (STT-A&B) Score

    Measures visual scanning and motor speed. The score is the time taken to complete the task. Full Scale Name: Shape trails test Minimum Value: 0 Maximum Value: None Higher Scores Mean: Slower completion time

    Time frame: Baseline, End of 2-week intervention, 4 weeks post-intervention, 12 weeks post-intervention

  13. Incidence and Severity of Adverse Events (AEs)

    Monitoring and reporting of all adverse events and serious adverse events related to the intervention, including their frequency, severity, and relationship to the study intervention

    Time frame: through study completion, an average of 14 weeks

07

Study locations

2 of 2 sites recruiting
08

References and documents

Publications

  • Lv X, Cheng Z, Wang Q, Gao F, Dai L, Du C, Liu C, Xie Q, Shen Y, Shi J; China Aging and Neurodegenerative Initiative (CANDI) Consortium. High burdens of phosphorylated tau protein and distinct precuneus atrophy in sporadic early-onset Alzheimer's disease. Sci Bull (Beijing). 2023 Nov 30;68(22):2817-2826. doi: 10.1016/j.scib.2023.10.019. Epub 2023 Oct 27. PubMed 37919158 ↗
  • Chen Q, Chen F, Long C, Zhu Y, Jiang Y, Zhu Z, Lu J, Zhang X, Nedelska Z, Hort J, Zhang B. Spatial navigation is associated with subcortical alterations and progression risk in subjective cognitive decline. Alzheimers Res Ther. 2023 Apr 25;15(1):86. doi: 10.1186/s13195-023-01233-6. PubMed 37098612 ↗
  • Zhao K, Wang D, Wang D, Chen P, Wei Y, Tu L, Chen Y, Tang Y, Yao H, Zhou B, Lu J, Wang P, Liao Z, Chen Y, Han Y, Zhang X, Liu Y. Macroscale connectome topographical structure reveals the biomechanisms of brain dysfunction in Alzheimer's disease. Sci Adv. 2024 Oct 11;10(41):eado8837. doi: 10.1126/sciadv.ado8837. Epub 2024 Oct 11. PubMed 39392880 ↗
  • Violante IR, Alania K, Cassara AM, Neufeld E, Acerbo E, Carron R, Williamson A, Kurtin DL, Rhodes E, Hampshire A, Kuster N, Boyden ES, Pascual-Leone A, Grossman N. Non-invasive temporal interference electrical stimulation of the human hippocampus. Nat Neurosci. 2023 Nov;26(11):1994-2004. doi: 10.1038/s41593-023-01456-8. Epub 2023 Oct 19. PubMed 37857775 ↗
  • Vassiliadis P, Beanato E, Popa T, Windel F, Morishita T, Neufeld E, Duque J, Derosiere G, Wessel MJ, Hummel FC. Non-invasive stimulation of the human striatum disrupts reinforcement learning of motor skills. Nat Hum Behav. 2024 Aug;8(8):1581-1598. doi: 10.1038/s41562-024-01901-z. Epub 2024 May 29. PubMed 38811696 ↗
  • Beanato E, Moon HJ, Windel F, Vassiliadis P, Wessel MJ, Popa T, Pauline M, Neufeld E, De Falco E, Gauthier B, Steiner M, Blanke O, Hummel FC. Noninvasive modulation of the hippocampal-entorhinal complex during spatial navigation in humans. Sci Adv. 2024 Nov;10(44):eado4103. doi: 10.1126/sciadv.ado4103. Epub 2024 Oct 30. PubMed 39475597 ↗
  • Grossman N, Bono D, Dedic N, Kodandaramaiah SB, Rudenko A, Suk HJ, Cassara AM, Neufeld E, Kuster N, Tsai LH, Pascual-Leone A, Boyden ES. Noninvasive Deep Brain Stimulation via Temporally Interfering Electric Fields. Cell. 2017 Jun 1;169(6):1029-1041.e16. doi: 10.1016/j.cell.2017.05.024. PubMed 28575667 ↗
  • Jack CR Jr, Andrews JS, Beach TG, Buracchio T, Dunn B, Graf A, Hansson O, Ho C, Jagust W, McDade E, Molinuevo JL, Okonkwo OC, Pani L, Rafii MS, Scheltens P, Siemers E, Snyder HM, Sperling R, Teunissen CE, Carrillo MC. Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup. Alzheimers Dement. 2024 Aug;20(8):5143-5169. doi: 10.1002/alz.13859. Epub 2024 Jun 27. PubMed 38934362 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Dec 2028, 41 months after the start.

Of 887 non-industry interventional studies with no phase under Alzheimer Disease, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 51. This study's planned 41 months is above that.

Counting every sponsor, half of 964 studies reached it within 29 months; a quarter within 15 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 6, 2025
First posted
Jun 22, 2025
StartActual
Jul 1, 2025
Primary completionEst.
Dec 31, 2028
CompletionEst.
Dec 31, 2029
Last update
Aug 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07031687
Responsible party
Ying Han (Professor, Xuanwu Hospital, Beijing) — Principal investigator
First posted
Jun 22, 2025
Start date
Jul 1, 2025
Primary completion
Dec 31, 2028 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
Aug 21, 2026

Study contacts

Ying Han, PhD
Contact
hanying@xwh.ccmu.edu.cn
+86 13621011941
Ying Han, PhD
principal investigator · Xuanwu Hospital of Capital Medical University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion